304 related articles for article (PubMed ID: 33497609)
21. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.
Dubrot J; Du PP; Lane-Reticker SK; Kessler EA; Muscato AJ; Mehta A; Freeman SS; Allen PM; Olander KE; Ockerman KM; Wolfe CH; Wiesmann F; Knudsen NH; Tsao HW; Iracheta-Vellve A; Schneider EM; Rivera-Rosario AN; Kohnle IC; Pope HW; Ayer A; Mishra G; Zimmer MD; Kim SY; Mahapatra A; Ebrahimi-Nik H; Frederick DT; Boland GM; Haining WN; Root DE; Doench JG; Hacohen N; Yates KB; Manguso RT
Nat Immunol; 2022 Oct; 23(10):1495-1506. PubMed ID: 36151395
[TBL] [Abstract][Full Text] [Related]
22. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
23. Retroviral Vectors for Cancer Gene Therapy.
Schambach A; Morgan M
Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
[TBL] [Abstract][Full Text] [Related]
24. Development of drug-inducible CRISPR-Cas9 systems for large-scale functional screening.
Sun N; Petiwala S; Wang R; Lu C; Hu M; Ghosh S; Hao Y; Miller CP; Chung N
BMC Genomics; 2019 Mar; 20(1):225. PubMed ID: 30890156
[TBL] [Abstract][Full Text] [Related]
25. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
[TBL] [Abstract][Full Text] [Related]
26. Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells.
Zhou X; Cui Y; Huang X; Yu Z; Thomas AM; Ye Z; Pardoll DM; Jaffee EM; Cheng L
Hum Gene Ther; 2003 Jul; 14(11):1089-105. PubMed ID: 12885348
[TBL] [Abstract][Full Text] [Related]
27. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
28. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
Lamers CH; Willemsen R; van Elzakker P; van Steenbergen-Langeveld S; Broertjes M; Oosterwijk-Wakka J; Oosterwijk E; Sleijfer S; Debets R; Gratama JW
Blood; 2011 Jan; 117(1):72-82. PubMed ID: 20889925
[TBL] [Abstract][Full Text] [Related]
29. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
Potts MA; McDonald JA; Sutherland KD; Herold MJ
Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
[TBL] [Abstract][Full Text] [Related]
30. A CRISPR Platform for Targeted In Vivo Screens.
Maranda V; Zhang Y; Vizeacoumar FS; Freywald A; Vizeacoumar FJ
Methods Mol Biol; 2023; 2614():397-409. PubMed ID: 36587138
[TBL] [Abstract][Full Text] [Related]
31. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
32. Detection of CRISPR/Cas9-Generated Off-Target Effect by Integration-Defective Lentiviral Vector.
Wang X; Wu Y; Yee JK
Methods Mol Biol; 2021; 2162():243-260. PubMed ID: 32926387
[TBL] [Abstract][Full Text] [Related]
33. Interrogating immune cells and cancer with CRISPR-Cas9.
Buquicchio FA; Satpathy AT
Trends Immunol; 2021 May; 42(5):432-446. PubMed ID: 33812776
[TBL] [Abstract][Full Text] [Related]
34. Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies.
Roth TL; Li PJ; Blaeschke F; Nies JF; Apathy R; Mowery C; Yu R; Nguyen MLT; Lee Y; Truong A; Hiatt J; Wu D; Nguyen DN; Goodman D; Bluestone JA; Ye CJ; Roybal K; Shifrut E; Marson A
Cell; 2020 Apr; 181(3):728-744.e21. PubMed ID: 32302591
[TBL] [Abstract][Full Text] [Related]
35. Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: methodological implications for immunotherapy.
Hanak L; Slaby O; Lauerova L; Kren L; Nenutil R; Michalek J
Med Sci Monit; 2009 Dec; 15(12):CR638-43. PubMed ID: 19946235
[TBL] [Abstract][Full Text] [Related]
36. Protocol for in vivo CRISPR screening using selective CRISPR antigen removal lentiviral vectors.
Lane-Reticker SK; Kessler EA; Muscato AJ; Kim SY; Doench JG; Yates KB; Manguso RT; Dubrot J
STAR Protoc; 2023 Mar; 4(1):102082. PubMed ID: 36861834
[TBL] [Abstract][Full Text] [Related]
37. Genetic screens and functional genomics using CRISPR/Cas9 technology.
Hartenian E; Doench JG
FEBS J; 2015 Apr; 282(8):1383-93. PubMed ID: 25728500
[TBL] [Abstract][Full Text] [Related]
38. Using CRISPR/Cas9 Technology for Manipulating Cell Death Regulators.
Kueh AJ; Herold MJ
Methods Mol Biol; 2016; 1419():253-64. PubMed ID: 27108444
[TBL] [Abstract][Full Text] [Related]
39. CRISPR Libraries and Screening.
Poirier JT
Prog Mol Biol Transl Sci; 2017; 152():69-82. PubMed ID: 29150005
[TBL] [Abstract][Full Text] [Related]
40. CRISPR screen in cancer: status quo and future perspectives.
He C; Han S; Chang Y; Wu M; Zhao Y; Chen C; Chu X
Am J Cancer Res; 2021; 11(4):1031-1050. PubMed ID: 33948344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
